There are currently 621 clinical trials in Sacramento, California looking for participants to engage in research studies. Trials are conducted at various facilities, including University of California Davis Comprehensive Cancer Center, University of California, Davis Medical Center, University of California, Davis and Sutter Medical Center Sacramento. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Virtual Reality Attention Management
NCT03221244
Recruiting
Problems with distraction are widespread in the 21st century, but for people with developmental delays or behavioral challenges they can have more damaging effects. For example, susceptibility to distraction is associated with worse school and social performance, lower high school graduation rates, and increased incidence of serious accidents. The investigators' goal is to improve understanding of distractibility and develop a targeted treatment. The proposed intervention is based on models of h... Read More
Gender:
All
Ages:
Between 8 years and 12 years
Trial Updated:
04/16/2023
Locations: UC Davis MIND Institute, Sacramento, California
Conditions: ADHD
Register for Updates
Assessment of the Effect of Coconut and Sunflower Seed Oil Derived Isosorbide Diseters and Colloidial Oatmeal
NCT05688735
Recruiting
The goal of this study is to compare coconut oil and sunflower seed oil derived isosorbide disesters and colloidal oatmeal, and observe their effect on pediatric atopic dermatitis among males and females aged 2-17.
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
04/12/2023
Locations: Integrative Skin Science and Research, Sacramento, California
Conditions: Atopic Dermatitis
Register for Updates
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
NCT03474497
Recruiting
This is a phase I/II study that will evaluate the safety and toxicity of this combinatorial approach. Eligible patients >18 years of age with histologically proven metastatic NSCLC, melanoma, RCC, or HNSCC who have failed PD-1 / PD-L1 checkpoint blockade therapy will be enrolled. Patients must have a candidate treatment lesion (subcutaneous, nodal, or visceral) accessible and safe for radiotherapy and serial intralesional injections as specified by the protocol. They must also have at least one... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/06/2023
Locations: UC Davis Medical Center, Sacramento, California +1 locations
Conditions: Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Register for Updates
GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS
NCT05266001
Recruiting
The GRACE-2 study is a prospective, multi-center, double-blind, randomized controlled trial of the drug GM-CSF vs placebo in children with sepsis-induced multiple organ dysfunction syndrome (MODS) who have immunoparalysis with mild to moderate inflammation.
Gender:
All
Ages:
Between 1 day and 17 years
Trial Updated:
02/07/2023
Locations: University of California - Davis, Sacramento, California
Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome
Register for Updates
Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
NCT05007418
Recruiting
This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2023
Locations: UC Davis, Sacramento, California
Conditions: Multiple Myeloma
Register for Updates
Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options
NCT03583164
Recruiting
A study to evaluate F901318 (study drug) for the treatment of invasive fungal infections in patients lacking suitable alternative treatment options.
Gender:
All
Ages:
16 years and above
Trial Updated:
11/30/2022
Locations: UC Davis Medical Center, Sacramento, California
Conditions: Invasive Fungal Infections
Register for Updates
Cardiovascular Effects of Prenatal Methamphetamine Exposure
NCT04616625
Recruiting
Methamphetamine (MA) is one of the commonly used drugs during pregnancy. Cardiovascular effects of MA include elevated blood pressure, acute vasospasm, atherosclerotic disease, structural and electrical remodeling of cardiac tissue leading to arrhythmias and heart failure, and pulmonary hypertension.1 In addition, MA can cause neurotoxicity with harmful effects on neurodevelopment in the children who had prenatal exposure.5-8 Currently neonatal providers do not perform detailed cardiovascular ev... Read More
Gender:
All
Ages:
All
Trial Updated:
11/28/2022
Locations: UC Davis Children's Hospital, Sacramento, California
Conditions: Methamphetamine Abuse, Newborn Complication | Patient | Neonatalology
Register for Updates
TruGraf® Long-term Clinical Outcomes Study
NCT04491552
Recruiting
This is a prospective, multi-center, observational study. Subjects will have OmniGraf™ (TruGraf® and TRAC™) testing at study enrollment and thereafter every 3 months. In addition subjects will have OmniGraf™ (TruGraf® and TRAC™) testing at any time there is a clinical suspicion of acute rejection. Data collection for the primary objective extends over a 2-year period.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/10/2022
Locations: University of California Davis, Sacramento, California
Conditions: Kidney Transplant Rejection
Register for Updates
A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
NCT04873232
Recruiting
To evaluate the durability of efficacy and long-term safety of intramuscular (IM) administration of Engensis or Placebo that was administered in the double-blind, randomized, VMDN-003-2 Placebo-controlled Phase 3 Study.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/03/2022
Locations: Clinical Trials Research - Sacramento, Sacramento, California
Conditions: Diabetic Peripheral Neuropathy
Register for Updates
2-level Cervical Disc Replacement Comparing Prodisc C SK & Vivo to Mobi-C
NCT04012996
Recruiting
A multi-center, prospective, randomized, controlled comparison of the prodisc C SK and prodisc C Vivo to the control, a similar, legally marketed total disc replacement device in subjects with symptomatic cervical disc disease (SCDD).
Gender:
All
Ages:
Between 18 years and 69 years
Trial Updated:
10/27/2022
Locations: Sutter Health, Sacramento, California
Conditions: Symptomatic Cervical Disc Disease
Register for Updates
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT04678648
Recruiting
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2022
Locations: UC Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer, Glioblastoma, Pancreatic Cancer
Register for Updates
Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT05479578
Recruiting
This phase I trial tests the safety and side effects of cyclophosphamide given together with dexamethasone in treating patients with castration resistant prostate cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving low doses of cyclophosphamide daily may reduce side effects. Dex... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
10/08/2022
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Register for Updates